Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-498
Closed -$13K 3204
2016
Q4
$13K Buy
498
+222
+80% +$6.47K ﹤0.01% 2603
2016
Q3
$11K Buy
+276
New +$35.6K ﹤0.01% 2882
2016
Q2
Sell
-267
Closed -$30.6K 3664
2016
Q1
$28K Buy
+267
New +$28.6K ﹤0.01% 2963
2015
Q4
Sell
-7
Closed -$1.08K 3920
2015
Q3
$1K Sell
7
-247
-97% -$55.4K ﹤0.01% 3832
2015
Q2
$57K Sell
254
-260
-51% -$45.7K ﹤0.01% 3252
2015
Q1
$85K Buy
514
+418
+435% +$67.9K ﹤0.01% 3148
2014
Q4
$11K Sell
96
-12,291
-99% -$1.28M ﹤0.01% 3672
2014
Q3
$1.03M Buy
12,387
+9,966
+412% +$901K 0.01% 2063
2014
Q2
$224K Buy
2,421
+2,204
+1,016% +$194K ﹤0.01% 3264
2014
Q1
$20K Buy
217
+145
+201% +$16.2K ﹤0.01% 3826
2013
Q4
$7K Buy
+72
New +$5.09K ﹤0.01% 3813

Other funds holding NVAX

Spot Trading's NVAX Position: Q1 2017 in Review

Spot Trading sold out of Novavax (NVAX) in Q1 2017, closing a stake of 498 shares — an estimated $13K sold.

Spot Trading first reported a position in NVAX in Q4 2013 and held it in 11 quarters. The position peaked at $1.03M in Q3 2014. 129 funds tracked by Wall St. Rank hold NVAX as of Q1 2017.

  • Spot Trading reported no remaining Novavax position as of Q1 2017 after selling out during the quarter.
  • Spot Trading sold 498 Novavax shares in Q1 2017, an estimated $13K.
  • Spot Trading first reported a position in Novavax in Q4 2013 and held it in 11 quarters.
  • Spot Trading's Novavax position peaked at $1.03M in Q3 2014.
  • 129 funds tracked by Wall St. Rank held Novavax as of Q1 2017.

Based on Spot Trading's 13F filing for Q1 2017, filed 1 May 2017.